FLGT Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -7.73% compared to Fulgent Genetics's net margin of -22.5%. Fulgent Genetics's return on equity of -3.78% beat Delcath Systems's return on equity of -117.89%.

Fulgent Genetics has a consensus price target of $20.00, signalling upside risk potential of 15.54%. On the other hand Delcath Systems has an analysts' consensus of $22.50 which suggests that it could grow by 79%. Given that Delcath Systems has higher upside potential than Fulgent Genetics, analysts believe Delcath Systems is more attractive than Fulgent Genetics.

Fulgent Genetics has a beta of 1.364, which suggesting that the stock is 36.367% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.729%.

Fulgent Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Fulgent Genetics quarterly revenues are $76.2M, which are larger than Delcath Systems quarterly revenues of $15.1M. Fulgent Genetics's net income of -$5.9M is lower than Delcath Systems's net income of -$3.4M. Notably, Fulgent Genetics's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics is 1.85x versus 9.94x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of -7.73% compared to Fulgent Genetics's net margin of -121.19%. Fulgent Genetics's return on equity of -3.78% beat Exact Sciences's return on equity of -34.11%.

Fulgent Genetics has a consensus price target of $20.00, signalling upside risk potential of 15.54%. On the other hand Exact Sciences has an analysts' consensus of $68.89 which suggests that it could grow by 58.55%. Given that Exact Sciences has higher upside potential than Fulgent Genetics, analysts believe Exact Sciences is more attractive than Fulgent Genetics.

Fulgent Genetics has a beta of 1.364, which suggesting that the stock is 36.367% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.136, suggesting its more volatile than the S&P 500 by 13.608%.

Fulgent Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Fulgent Genetics quarterly revenues are $76.2M, which are smaller than Exact Sciences quarterly revenues of $713.4M. Fulgent Genetics's net income of -$5.9M is higher than Exact Sciences's net income of -$864.6M. Notably, Fulgent Genetics's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics is 1.85x versus 2.90x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -7.73% compared to Fulgent Genetics's net margin of 16.94%. Fulgent Genetics's return on equity of -3.78% beat Illumina's return on equity of -35.09%.

Fulgent Genetics has a consensus price target of $20.00, signalling upside risk potential of 15.54%. On the other hand Illumina has an analysts' consensus of $130.64 which suggests that it could grow by 66.66%. Given that Illumina has higher upside potential than Fulgent Genetics, analysts believe Illumina is more attractive than Fulgent Genetics.

Fulgent Genetics has a beta of 1.364, which suggesting that the stock is 36.367% more volatile than S&P 500. In comparison Illumina has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.551%.

Fulgent Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

Fulgent Genetics quarterly revenues are $76.2M, which are smaller than Illumina quarterly revenues of $1.1B. Fulgent Genetics's net income of -$5.9M is lower than Illumina's net income of $187M. Notably, Fulgent Genetics's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics is 1.85x versus 2.86x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -7.73% compared to Fulgent Genetics's net margin of -14.37%. Fulgent Genetics's return on equity of -3.78% beat Star Equity Holdings's return on equity of -17.45%.

Fulgent Genetics has a consensus price target of $20.00, signalling upside risk potential of 15.54%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 323.73%. Given that Star Equity Holdings has higher upside potential than Fulgent Genetics, analysts believe Star Equity Holdings is more attractive than Fulgent Genetics.

Fulgent Genetics has a beta of 1.364, which suggesting that the stock is 36.367% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.205%.

Fulgent Genetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

Fulgent Genetics quarterly revenues are $76.2M, which are larger than Star Equity Holdings quarterly revenues of $17.1M. Fulgent Genetics's net income of -$5.9M is lower than Star Equity Holdings's net income of -$2.5M. Notably, Fulgent Genetics's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics is 1.85x versus 0.14x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.